IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Trial ID or NCT#

NCT06112314

Status

not recruiting iconNOT RECRUITING

Purpose

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.

Official Title

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Allison Betof, MD, PhD, FASCO
Allison Betof, MD, PhD, FASCO
Cutaneous oncology specialist, Melanoma specialist, Medical oncologist
Associate Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

Contact

Claire Billman

View on ClinicalTrials.gov